Education
About Us
Working with TipRanks
Follow Us
ProQR (PRQR)
NASDAQ:PRQR
PRQR Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PRQR Stock 12 Month Forecast
Average Price Target
$8.50
▲(482.19% Upside)
| Highest Price Target$12.00 | Average Price Target$8.50 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$5
Buy
242.47%
Upside
Reiterated
12/17/25
H.C. Wainwright
$12
Buy
721.92%
Upside
Reiterated
12/10/25
Oppenheimer
$9
Buy
516.44%
Upside
Reiterated
11/11/25
Chardan Capital
$4
Buy
173.97%
Upside
Reiterated
11/06/25
Citizens JMP
$8
Buy
447.95%
Upside
Reiterated
10/15/25
Cantor Fitzgerald
$8
Buy
447.95%
Upside
Reiterated
07/17/25
JonesTrading
$11
Buy
653.42%
Upside
Reiterated
05/17/25
We are at ASGCT this week and caught ProQR's oral session on cholestatic diseases and their two posters on Rett and MASH. Cholestatic Diseases: ProQR presented preclinical data and Ph1 trial design for AX-0810, an RNA editing oligo for cholestatic diseases. Presentation was substantially similar to OTS Meeting, and supports 0810's potential to reduce liver bile accumulation in primary sclerosing cholangitis (PSC). AX-0810 introduces a de novo edit, so Ph1 healthy volunteer data should give us a good picture of in vivo editing capabilities.
Citi
$4
Buy
173.97%
Upside
Upgraded
03/07/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$5
Buy
242.47%
Upside
Reiterated
12/17/25
H.C. Wainwright
$12
Buy
721.92%
Upside
Reiterated
12/10/25
Oppenheimer
$9
Buy
516.44%
Upside
Reiterated
11/11/25
Chardan Capital
$4
Buy
173.97%
Upside
Reiterated
11/06/25
Citizens JMP
$8
Buy
447.95%
Upside
Reiterated
10/15/25
Cantor Fitzgerald
$8
Buy
447.95%
Upside
Reiterated
07/17/25
JonesTrading
$11
Buy
653.42%
Upside
Reiterated
05/17/25
We are at ASGCT this week and caught ProQR's oral session on cholestatic diseases and their two posters on Rett and MASH. Cholestatic Diseases: ProQR presented preclinical data and Ph1 trial design for AX-0810, an RNA editing oligo for cholestatic diseases. Presentation was substantially similar to OTS Meeting, and supports 0810's potential to reduce liver bile accumulation in primary sclerosing cholangitis (PSC). AX-0810 introduces a de novo edit, so Ph1 healthy volunteer data should give us a good picture of in vivo editing capabilities.
Citi
$4
Buy
173.97%
Upside
Upgraded
03/07/25
Best Analysts Covering ProQR
3 Months
xxx
Success Rate
4/7 ratings generated profit
Average Return
-2.69%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -2.69% per trade.
1 Year
Success Rate
11/20 ratings generated profit
Average Return
+8.04%
a rating ―
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +8.04% per trade.
2 Years
xxx
Success Rate
8/20 ratings generated profit
Average Return
-7.43%
a xxx
rating ―
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -7.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PRQR Analyst Recommendation Trends
Rating
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Strong Buy
5
6
8
6
2
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
6
8
6
2
Each month's total comprises the sum of three months' worth of ratings.
PRQR Financial Forecast
PRQR Stock Forecast FAQ
What is PRQR’s average 12-month price target, according to analysts?
Based on analyst ratings, ProQR’s 12-month average price target is 8.50.
What is PRQR’s upside potential, based on the analysts’ average price target?
ProQR has 482.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PRQR a Buy, Sell or Hold?
ProQR has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is ProQR’s price target?
The average price target for ProQR is 8.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents 482.19% Increase from the current price of $1.46.
The highest analyst price target is $12.00 ,the lowest forecast is $5.00. The average price target represents 482.19% Increase from the current price of $1.46.
What do analysts say about ProQR?
ProQR’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of PRQR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.